Technological developments such as next-generation sequencing, super-resolution imaging, and systems-level computational approaches have resulted in great leaps in our understanding of the immune system. Despite these advances, many autoimmune diseases lack effective treatments; and the current pandemic has shown the critical need to better understand the immune system in order to harness it to develop vaccines and therapeutics.
Developing targeted therapies for rare cardiomyopathies is challenging: difficulties identifying patients, delivering therapeutics, and accessing heart tissue results in a 50% mortality rate 5 years after diagnosis. Early, accurate disease detection and classification can significantly improve outcomes for patients with rare cardiomyopathies. Achieving these goals requires multiple novel technologies to coalesce that will enable early patient identification, deepen our understanding of the disease process, improve modeling of human pathophysiology, accelerate testing of drug candidates, and leverage novel therapeutic modalities to target the heart specifically, safely and effectively.
This two-day conference will convene industry scientists, academics, and clinicians to understand the integration of artificial intelligence and engineered tissues for safe and effective delivery of novel therapeutics for patients with arrhythmogenic, hypertrophic, and dilated cardiomyopathies.
Since 2004, the Dr. Paul Janssen Award for Biomedical Research has honored scientists who have made a transformational contribution toward the improvement of human health. This prestigious award honors the legacy of Dr. Paul Janssen, an exceptionally gifted and passionate scientist who revolutionized modern medicine and inspired a new generation of researchers.
This half-day virtual symposium will celebrate the 2023 Honoree, Dr. Robert Langer, and his pioneering work. You can learn more about Dr. Langer below. We are proud to offer this event free of cost to anyone interested in celebrating scientific innovation. Registration is required.
Developing targeted therapies for rare cardiomyopathies is challenging: difficulties identifying patients, delivering therapeutics, and accessing heart tissue results in a 50% mortality rate 5 years after diagnosis. Early, accurate disease detection and classification can significantly improve outcomes for patients with rare cardiomyopathies. Achieving these goals requires multiple novel technologies to coalesce that will enable early patient identification, deepen our understanding of the disease process, improve modeling of human pathophysiology, accelerate testing of drug candidates, and leverage novel therapeutic modalities to target the heart specifically, safely and effectively.
This two-day conference will convene industry scientists, academics, and clinicians to understand the integration of artificial intelligence and engineered tissues for safe and effective delivery of novel therapeutics for patients with arrhythmogenic, hypertrophic, and dilated cardiomyopathies.
This three-day meeting will convene immuno-oncology experts across academia and industry to share cutting-edge discoveries and to advance the development of novel cancer immunotherapies.
Global experts explore the gene regulation of hemoglobin; the pathophysiology of iron overload, clinical management, emerging therapies, co-morbidities, and updates from clinical trials using gene addition, gene editing, and alternative donor source hematopoietic stem cell transplantation, among other topics central to thalassemia syndromes.
The Ross Prize in Molecular Medicine was established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine. The 2022 virtual symposium celebrates the work of award winners—Katalin Karikó, PhD, and Drew Weissman, MD, PhD for their pioneering mRNA research. Presentations will also be delivered by other leaders in the field.
Dr. Zhuang was recently chosen as the winner of The Foundation for the National Institutes of Health’s (FNIH) 2021 Lurie Prize in Biomedical Sciences. In this talk, Dr. Zhuang will share her personal journey and experience of becoming a scientist, including how she has worked with her mentors and why pursuing a career in STEM is vital to today’s world.
This two-day conference will convene leaders in vaccinology, virology, immunology, biotechnology, microbiology, systems biology, and health policy. Session topics include a look back at advances in vaccine development, updates from present-day vaccinology, a discussion on how vaccine development can be strengthened based on COVID-19 vaccine learnings, pharma company pipeline updates, next generation vaccine adjuvants, improving immune measures, and more.
Researchers are opening up new avenues in our understanding of pain. This symposium will explore dissection of central pain circuits, genetics, biomarkers, emerging therapies, neuro-immune and auto-immune mechanisms, sex and ethnic differences, and innovations in the identification and development of new therapeutic targets for pain.